Geneva, May 18 -- International Clinical Trials Registry received information related to the study (ChiCTR2600124282) titled 'Rituximab-induced sustained B-cell depletion for the treatment of refractory nephrotic syndrome in children' on May 9.
Study Type: Interventional study
Study Design:
Non randomized control
Primary Sponsor: Xiangya Hospital, Central South University
Condition:
Pediatric Nephrotic Syndrome
Intervention:
Group 1 (retrospective section):none
Group 2:Standard-dose rituximab induction in month 1, followed by standard-dose rituximab maintenance every 6 months
Group 3:After standard-dose rituximab induction in the first month, maintenance therapy with standard-dose rituximab is administered every 3 months within th...